Chronic Myeloid Leukemia Excellence Forum

Chronic Myeloid Leukemia

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Interview

Data Support Using Bosutinib Therapy for Treatment of Chronic-Phase CML

07/21/2020

Sonia Amin Thomas, PharmD, BCOP, discusses data regarding the safety and efficacy of bosutinib therapy for patients with chronic-phase CML.

Sonia Amin Thomas, PharmD, BCOP,...

07/21/2020

Oncology

Podcasts

Interim Analysis Suggests Correlation Between Ponatinib Dosing and Efficacy in CML

06/11/2020

Jorge Cortes, MD, discusses results from an interim analysis of the OPTIC trial, evaluating the association between ponatinib exposure, efficacy, and safety with response-based dose reduction in CML.

Jorge Cortes, MD, discusses...

06/11/2020

Oncology

Interview

Asciminib Shows Activity in Pretreated Patients With CML

04/27/2020

Michael Mauro, MD, spoke about the findings of a phase 1 trial evaluating the use of asciminib, an ABL1 kinase inhibitor, in heavily pretreated CML.

Michael Mauro, MD, spoke about...

04/27/2020

Oncology

Podcasts

TKI Discontinuation in Patients With CML

04/07/2020

Ehab Atallah, MD, discusses the do’s and don’ts of TKI treatment discontinuation in patients with CML.

Ehab Atallah, MD, discusses the...

04/07/2020

Oncology

Podcasts

Post-Transplant TKI Salvage Therapy Provides Significant Survival Benefit Following Relapse in CML

03/23/2020

Sarah Schmidt, PharmD, BCPS, BCOP, discusses results from a retrospective analysis evaluating the role of donor lymphocyte infusion in patients with CML who relapse post-transplant in the TKI era.

Sarah Schmidt, PharmD, BCPS,...

03/23/2020

Oncology

Podcasts

Novel ABL1 Kinase Inhibitor Active in Heavily Pretreated CML

02/01/2020

Michael Mauro, MD, discusses results from a phase 1 trial which evaluated asciminib, an ABL1 kinase inhibitor, in patients with heavily pretreated CML.

Michael Mauro, MD, discusses...

02/01/2020

Oncology

Resource

Chronic Myelogenous Leukemia Treatment (PDQ®)–Health Professional Version

01/29/2020

Chronic myelogenous leukemia treatments include tyrosine kinase inhibitors, high-dose therapy with allogeneic transplantation, and other medications. Get detailed information about chronic myelogenous leukemia (CML) treatment options in this...

Chronic myelogenous leukemia...

01/29/2020

Oncology

Podcasts

Gabriella Hobbs, MD, Discusses Treatment Options for Patients With CML

11/08/2018

In this 3-part podcast series, Gabriela Hobbs, MD, answers a series of questions about how she treats patients with CML.

In this 3-part podcast series,...

11/08/2018

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology